(NASDAQ: BLTE) Belite Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.08%.
Belite Bio's earnings in 2026 is -$77,611,000.On average, 10 Wall Street analysts forecast BLTE's earnings for 2026 to be -$132,166,530, with the lowest BLTE earnings forecast at -$165,007,528, and the highest BLTE earnings forecast at -$114,420,274. On average, 10 Wall Street analysts forecast BLTE's earnings for 2027 to be -$22,805,375, with the lowest BLTE earnings forecast at -$170,790,502, and the highest BLTE earnings forecast at $240,406,496.
In 2028, BLTE is forecast to generate $142,347,711 in earnings, with the lowest earnings forecast at $76,720,790 and the highest earnings forecast at $294,105,541.